Vericel Corporation
Vericel Corporation is a biopharmaceutical company developing cellular therapies for sports medicine and severe burn care markets in North America. Products include MACI for knee cartilage repair, Epicel for skin replacement, and NexoBrid for eschar removal in thermal burns.
Overview
Strengths
- The company has high returns. ROIC (14.88%) is higher than the sector mean (6.02%).
Weaknesses
- With a depreciation Potential of -94.66%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (204.36) is significantly higher than the sector mean (91.15).
- The company has high debt. Net Debt to EBITDA Ratio (1.46) is higher than the sector mean.
- EV/EBITDA (128.82) is significantly higher than the sector mean (85.60).
- EV/EBIT (192.55) is significantly higher than the sector mean.
- EBITDA Margin (7.01%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 204.4 |
| EV/EBITDA | 128.8 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 14.9% |
| Net Debt/EBITDA | 1.5 |